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The objectives of this prospective, randomized study were to evaluate the efficacy and tolerability of the
short-term use of medium-chain triglyceride/long-chain triglyceride (MCT/LCT) fat emulsions, and to
compare the hematologic and biochemical effects of MCT/LCT fat emulsions with LCT fat emulsions in
gastrointestinal (GI) tract cancer patients following surgery. Thirty patients with GI tract cancer requiring
total parenteral nutrition (TPN) were equally randomized to receive MCT/LCT or LCT emulsions for 7 days.
After 7 days, no sign of complications directly related to administration of fat emulsions was observed and
there were no marked differences in anthropometry, length of hospital stay, and surgical complication rates
between the two groups. However, MCT/LCT significantly improved plasma prealbumin concentration
(p = 0.005). Changes in complements C3 and C4, total lymphocyte count, and immunoglobulins after TPN
were not significantly different between the groups. Serum triglyceride and cholesterol levels remained
constant. The serum insulin level in the MCT/LCT group was higher than in the LCT group (p = 0.048). Our
data revealed that MCT/LCT fat emulsions significantly enhanced nutritional status in patients with GI tract
cancer, indicated by higher prealbumin levels, which might be partially due to the higher circulating insulin
levels in the MCT/LCT group.
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Surgical intervention in gastrointestinal (GI) tract cancer
patients, especially in those with serious malnutrition,
induces complex physiologic changes that lead to catabolism
and loss of body cell mass. To avoid severe metabolic
distress, therapy with total parenteral nutrition (TPN) may
be prescribed. An integral component of TPN regimens,
lipid emulsions predominantly include long-chain
triglycerides (LCT) with 16–20 carbon atoms. These essential
and mainly unsaturated fatty acids provide non-protein
calories and, thus, reduce the caloric need for glucose and
prevent fatty acid deficiency syndrome [1]. However,
because LCT is involved in the metabolism of prostaglandin
and leukotriene [2], and in diminishing reticuloendothelial
system function [3,4], it has been fairly well documented as
triggering immunosuppression and decreasing cell-
mediated immunity [5–8]. In addition, much of the infused
LCT is not readily oxidized, due to the relative deficiency of
carnitine or inhibition of the carnitine acyltransferase system
for translocating LCT across the inner mitochondrial
membrane in critically ill patients [9].
© 2005 Elsevier. All rights reserved.
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Since the 1970s, triglyceride emulsions containing
medium-chain triglycerides (MCT) and LCT have been
used as lipid substrates in TPN [9–12]. MCT, with 6 to 10
carbon atoms, is easily oxidized, and its entry into
mitochondria is carnitine independent [12,13]. Thus,
hydrolysis of MCT is faster than that of LCT and,
consequently, MCT fatty acids are more rapidly made
available to tissues [12–14]. Also, tissue uptake of MCT is
faster due to the weaker albumin binding of MCT [15].
Because it is not involved in prostaglandin and leukotriene
metabolism, MCT may also provide a better immune-system
profile in these patients [8,16–19]. MCT/LCT emulsions
offer significant advantages over LCT emulsions on
metabolic effects in vivo, but this concept remains
controversial in specific patient populations [20]. Therefore,
this study was designed to delineate the efficacy and toler-
ability of short-term use of MCT/LCT emulsions, and
whether or not modification of the fat composition
(MCT/LCT vs LCT) in surgical GI tract cancer patients
improved nutritional status by reducing protein catabolism.
We also evaluated the side effects, including liver dysfunc-
tion and lipid metabolism, the impact on immunity, and the
outcome by measuring the length of hospital stay and
mortality rate in a homogenous group of patients.
PATIENTS AND METHODS
Patients
For this prospective randomized clinical trial at the Kaohsiung
Medical University Hospital, inclusion criteria were: weight
loss was greater than or equal to 10% of the usual body
weight in the past 6 months, presence of histologically proven
cancer, and major planned elective surgery. Patients were
excluded if they were less than 18 years old; had cardiac
dysfunction (New York Heart Association functional class
> III, stroke history), hepatic dysfunction (Child-Pugh > 2),
or renal dysfunction (serum creatinine concentration
> 265 +mol/L, hemodialysis, or both); were pregnant; or
had ongoing infection. The hospital’s ethics committee
approved the study protocol, and written informed consent
was obtained from all subjects and/or guardians.
Procedures
All patients who fulfilled the selection criteria were
randomly assigned to receive TPN with MCT/LCT or LCT.
All patients had a central venous catheter placed during the
operation. At the time of admission, we recorded the patient’s
age and gender, co-morbidity, actual and usual body
weight, hemoglobin concentration, serum glucose, serum
creatinine, serum electrolytes, urine urea nitrogen (UUN),
serum total protein, serum albumin and prealbumin, and
total lymphocyte count (TLC). Duration of surgery, operative
blood loss, the frequency and amount of homologous blood
transfusions, and duration of postoperative hospital stay
were also recorded. The nutritional regimen was designed to
be isocaloric and isonitrogenous over 1 week, and to deliver,
for an average individual with a weight of 70 kg, 1.2 g amino
acid/kg/day and 26 kcal/kg/day. Patients received 0.88 g
fat/kg/day, the MCT/LCT group from Lipofundin 20%
(200 g/L fat emulsion containing 100 g/L soybean oil LCT
and 100 g/L MCT; B. Braun, Melsungen, Germany) and the
LCT group from Intralipid 20% (200 g/L LCT; Otsuka,
Tokushima, Japan). Parenteral nutrition included electrolytes,
vitamins, and trace elements according to current standards.
TPN was started on the afternoon after surgery (at 6:00 pm)
and was continued for 1 week. All patients received concurrent
prophylactic antibiotics. Surgical staff diagnosed any
postoperative complications, both infectious and
noninfectious. All infectious complications were
demonstrated by microbiologic analysis and positive culture.
Re-laparotomy, complications requiring transfer of the patient
to the intensive care unit during the postoperative course, or
percutaneous drainage of deep infected collections by
interventional radiologic procedures were defined as major
complications. The primary endpoint was occurrence of
postoperative complications. Length of postoperative stay,
adverse effects, and treatment switchover were secondary
endpoints.
Nutrition assessment
Nutritional status was assessed by trained nutrition nurses
within 24 hours of admission (Day 0) and after 7 days
(Day 7). Nutritional status was determined from
anthropometric and biochemical measurements and from
medical records. Anthropometric measurements included
height and weight on admission, triceps skinfold thickness
(TSF), and mid-arm circumference (MAC). The mid-arm
muscle circumference was calculated as:
   Mid-arm muscle
circumference (mm)
Biochemical measurements included serum albumin and
prealbumin and TLC. A 24-hour urine collection was
obtained to measure UUN and creatinine. The nitrogen
balance was derived from:
      Nitrogen
balance (g/day)
= MAC (mm) – (TSF [mm] = 3.14)
nitrogen intake –
(UUN + 4 g obligatory loss)
=
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The following values were considered normal for our
laboratory: serum albumin, 3.5–5.0 g/dL; prealbumin, 18–
43 mg/dL; and TLC greater than 1500/mm3.
Statistical analysis
Results are expressed as mean (  standard deviation. All
data were analyzed using the Statistical Package for the
Social Sciences version 8.0 software (SPSS Inc., Chicago, IL,
USA). The Chi-squared test was used to compare clinical
characteristics in the two groups, while Student’s t test was
used to compare parameters. A probability of less than 0.05
was considered statistically significant.
RESULTS
Between January 1997 and March 1999, 30 patients with GI
tract cancer were enrolled in this study, 15 in the MCT/LCT
group with an average age of 63.7 years, and 15 in the LCT
group with an average age of 71.0 years. The two groups
were well balanced for baseline characteristics (Table 1).
Both emulsions were well tolerated by all patients, and no-
one left the study due to adverse reactions. The use of
different lipid emulsions had no effect on overall
complications and mortality (all p > 0.05) (Table 1). Length
of hospital stay did not differ significantly between the two
groups, at 26.8 days for the MCT/LCT group and 27.6 days
for the LCT group (p > 0.05). In-hospital mortality was 6.7%
for each group. Comparison of the anthropometry profiles
showed no difference between the groups (p > 0.05) (Table
2). However, a marked improvement in the prealbumin
level was found in the MCT/LCT group after 7 days of TPN
(p = 0.005) (Table 3). Changes in transferrin and nitrogen
balance were not significantly different.
After 7 days of the study, we observed significant alteration
in liver function tests, including cholestasis enzymes
(a-glutamyltranspeptidase and alkaline phosphatase) and
bilirubin level, in both groups, but the modifications were
similar in both groups (Table 4). Insulin levels were increased
in the MCT/LCT group (p = 0.048) (Table 5). Four patients
in each group received exogenous insulin and were, therefore,
excluded from the analysis of insulin concentrations. Needs
for exogenous insulin were similar in both groups. We
further analyzed the immunologic profiles including
lymphocytes, immunoglobulins (IgG, IgM, IgA) and
complements (C3, C4) before and after use of TPN. Our data
showed that, after 7 days of parenteral nutrition, lymphocyte
counts declined in both groups, C3 and C4 levels decreased
in the LCT group, while IgG, IgM, and IgA markedly
Table 1. Patient and clinical characteristics in the two groups
MCT/LCT LCT
(n = 15) (n = 15)
Age, mean (yrs) 63.7 71.0
Gender
Male 10 14
Female 5 1
Gastric cancer
Stage
II 0 1
III 1 6
IV 4 3
Colon cancer
Dukes’ stage
B1 1 1
B2 6 0
C2 1 4
D 2 0
BT (U) 1.06 1.5
LOS, mean (d) 26.8 27.6
Complications (n) 2 5
Mortality (n) 1 1
MCT = medium-chain triglycerides; LCT = long-chain triglycerides;
BT = blood transfusion; LOS = length of stay.
Table 2. Comparison of anthropometry profiles in the two
groups (mean ( standard deviation)
MCT/LCT LCT p*
Body weight (kg)
Day 0 53.6 ( 11.4 54.6 ( 14.2
Day 7 52.5 ( 11.0 53.5 ( 13.0 0.496
TSF (mm)
Day 0 12.4 ( 8.1 12.0 ( 4.2
Day 7 12.9 ( 8.1 12.5 ( 4.7 0.848
MAC (cm)
Day 0 23.6 ( 3.4 24.4 ( 3.7
Day 7 23.4 ( 3.2 23.8 ( 3.9 0.262
MCT = medium-chain triglycerides; LCT = long-chain triglycerides;
TSF = triceps skinfold thickness; MAC = mid-arm circumference.
*Paired t test.
increased in both groups, and C3 and C4 increased in the
MCT/LCT group. However, the differences between groups
did not reach statistical significance (Table 6).
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DISCUSSION
Our data revealed that, after 7 days of administration of
TPN with either MCT/LCT or LCT emulsions, there was
no difference in overall postoperative complications and
length of hospital stay (Table 1) or in anthropometry
profiles (Table 2). However, further evaluation in a larger
patient population with long-term follow-up is needed
because the number of patients in this study was relatively
small, and the duration of TPN administration was only
7 days.
The greater improvement of serum prealbumin level in
the MCT/LCT group (11.9 ( 0.9 to 20.1 ( 1.5 vs 15.3 ( 1.8 to
15.0 ( 1.8 in the LCT group; p = 0.005) documented a better
recovery of nutritional status (Table 3), even with a lower
initial prealbumin level. Although the serum prealbumin
level can be altered by systemic inflammatory status,
prealbumin is recognized as the most sensitive measure
and the test of choice for early assessment and intervention
to enhance the care of hospitalized individuals [21,22].
The randomization and similar complication rate and
length of hospital stay indicated that inflammatory status
was comparable in the two groups, so the smaller increase
in prealbumin in the LCT group might reflect poorer
nutritional status.
The nitrogen balance and plasma transferrin level in our
series did not change in both groups. Nitrogen balance is
the most common clinical method for assessing protein
turnover and the primary aim of nutritional support should
be the achievement of a positive nitrogen balance [23,24].
The beneficial effects on protein metabolism exhibited by
Table 3. Comparison of nutrition parameters in the two
groups (mean ( standard deviation)
MCT/LCT LCT p*
(n = 15) (n = 15)
Albumin (g/dL)
Day 0 3.6 ( 0.2 3.3 ( 0.1 0.911
Prealbumin (mg/dL)
Day 0 11.9 ( 0.9 15.3 ( 1.8
Day 7 20.1 ( 1.5 15.0 ( 1.8 0.005
Transferrin (mg/dL)
Day 0 150.6 ( 13.6 161.7 ( 14.6
Day 7 166.9 ( 14.4 147.8 ( 16.6 0.167
Nitrogen balance (g/D)
Day 0 –2.1 ( 1.2 –4.8 ( 1.7
Day 7 –1.6 ( 2.5 –0.4 ( 1.7 0.139
MCT = medium-chain triglycerides; LCT = long-chain triglycerides.
*Paired t test.
Table 4. Comparison of biochemistry and liver function tests
in the two groups (mean ( standard deviation)
MCT/LCT LCT p*
GOT (IU/L)
Day 0 33.6 ( 6.2 29.2 ( 3.0
Day 7 51.2 ( 7.1 59.5 ( 16.8 0.496
GPT (IU/L)
Day 0 20.3 ( 3.4 19.4 ( 2.8
Day 7 47.0 ( 9.0 43.0 ( 12.6 0.848
ALP (IU/L)
Day 0 242.0 ( 80.2 194.3 ( 17.4
Day 7 420.7 ( 67.9 374.2 ( 39.7 0.986
a-GT (IU/L)
Day 0 30.3 ( 54.1 22.7 ( 18.4
Day 7 164.2 ( 152.1 110.1 ( 88.5 0.248
T-Bil (mg/dl)
Day 0 0.7 ( 0.2 0.7 ( 0.1
Day 7 0.9 ( 0.2 1.5 ( 0.4 0.137
Prothrombin time
Day 0 11.4 ( 0.2 11.8 ( 1.0
Day 7 11.3 ( 1.4 12.3 ( 0.3 0.112
MCT = medium-chain tr iglycerides;  LCT = long-chain
triglycerides; GOT = glutamyl oxaloacetic transaminase; GPT =
glutamyl pyruvic transaminase; ALP = alkaline phosphatase;
a-GT = a-glutamyltranspeptidase; T-Bil = total bilirubin.
*Paired t test.
Table 5. Comparison of plasma glucose and insulin
concentrations in the two groups (mean ( standard deviation)
MCT/LCT LCT p*
Glucose (g/dL)
Day 0 126.4 ( 8.2 129.4 ( 9.1
Day 7 142.7 ( 12.6 145.3 ( 10.2 0.964
Insulin (IU/mL)
Day 0 14.1 ( 2.6 22.5 ( 5.2
Day 7 20.7 ( 7.0 18.3 ( 1.9 0.048
C-peptide
Day 0 4.5 ( 5.2 4.7 ( 3.2
Day 7 5.8 ( 4.4 5.6 ( 4.0 0.946
MCT = medium-chain triglycerides; LCT = long-chain triglycerides.
*Paired t test.
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Table 6. Comparison of the immunologic profiles in the two groups (mean ( standard deviation)
Day 0 Day 7 6E p*
Total lymphocyte count
MCT/LCT 16.8 ( 12.4% 14.3 ( 5.5% –2.6%
LCT 18.3 ( 7.8% 11.9 ( 6.2% –6.4% 0.356
IgG (mg/dL)
MCT/LCT 1,189.9 ( 509.2 1,445.7 ( 506.9 +255.9%
LCT 1,290.9 ( 228.6 1,475.8 ( 315.8 +184.9% 0.515
IgA (mg/dL)
MCT/LCT 287.4 ( 145.3 344.0 ( 143.1 +56.6%
LCT 319.4 ( 157.2 385.3 ( 187.5 +65.9% 0.771
IgM (mg/dL)
MCT/LCT 105.2 ( 58.3 140.9 ( 79.9 +35.7%
LCT 91.4 ( 34.8 103.9 ( 52.1 +12.5% 0.107
C3 (mg/dL)
MCT/LCT 94.8 ( 18.3 122.3 ( 30.7 +27.5%
LCT 160.3 ( 271.2 103.4 ( 32.5 –56.9% 0.223
C4 (mg/dL)
MCT/LCT 27.1 ( 9.9 29.0 ( 10.5 +1.9%
LCT 21.7 ( 5.2 20.5 ( 7.3 –1.1% 0.172
*Paired t test. 6E = % difference; MCT = medium-chain triglycerides; LCT = long-chain triglycerides; Ig = immunoglobulin; C3 = complement 3;
C4 = complement 4.
MCT are not well understood and different nitrogen-sparing
mechanisms may be involved. MCTs are hydrolyzed and
cleared faster than LCTs in normal volunteers, surgical
patients, and critically ill subjects [25–27]. Moreover, the
oxidation rate of medium-chain fatty acids (MCFAs) is
considered higher than that of long-chain fatty acids (LCFA).
Nevertheless, the lipid emulsion did not affect nitrogen
balance after a short period of nutritional support in some
studies [20,28,29].
Derangement of liver function is a common untoward
effect in patients receiving TPN with or without lipids.
Because it is not stored in the liver, does not interfere with
bile acid composition, and produces ketone bodies as fuel
for the enterocyte to diminish bacterial translocation, some
investigators have hypothesized that MCT might reduce
the hepatic dysfunction caused by TPN [30]. Some clinical
trials have confirmed this hypothesis [31,32], whereas others,
including this study, have not [33,34]. The hepatic enzymes
and cholestasis enzymes were markedly elevated in both
groups in this study, as was the bilirubin level. Nevertheless,
our short-term use of fat emulsions might not be long
enough to demonstrate any differences.
The finding of higher levels of circulating insulin on Day
7 in the MCT group was compatible with previous obser-
vations [25,33]. Serum ketone bodies increased in both normal
and diabetic rats after an MCT diet for 3 days, and the serum
insulin levels of MCT-fed rats tended to be higher than in
normal animals [35]. MCT feed caused an enhancement of
fatty acid synthetase and malic enzyme in the liver of normal
rats. The elevated levels of insulin might be explained by the
direct effect of MCFAs or ketone bodies on pancreatic cells to
stimulate the release of insulin [25,33]. However, despite
higher plasma insulin levels in the MCT group, plasma
glucose and insulin requirements were similar in both groups.
Rett et al suggest that the inhibition of muscular glucose
uptake by infusion of MCT may explain the neutral influence
on glucose levels when using MCT/LCT [36]. Insulin is the
major endogenous anabolic hormone in the body, and several
studies have found reduced nitrogen loss with insulin
administration in injured patients [37]. This elevation of
plasma insulin levels could be another factor explaining the
MCT promotion of nitrogen retention in these patients.
Excess use of LCT fat emulsions might cause
overproduction of prostaglandins and Th1-type cytokines,
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subsequently inducing immunosuppression and decreasing
cell-mediated immunity [2]. In our study, there was no
difference in immunologic profiles between the two groups,
which might be explained by less-stressed patients with
elective surgery in our series. Furukawa et al found an
amplified level of interleukin-6 and a decreased level of
concanavalin A- or phytohemagglutinin-stimulated
lymphocyte proliferation with LCT fat emulsion in severely
stressed patients undergoing esophagectomy, but not in
moderately stressed patients who underwent gastrectomy
or colectomy [38].
In conclusion, our results indicated that modification
of the fat composition (MCT/LCT vs LCT) of TPN for GI
tract cancer patients improved nutritional status, as
indicated by a higher prealbumin level, which might be
partially due to the higher circulating insulin levels in the
MCT/LCT group.
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